Copyright
©2010 Baishideng Publishing Group Co.
World J Gastrointest Endosc. Nov 16, 2010; 2(11): 362-368
Published online Nov 16, 2010. doi: 10.4253/wjge.v2.i11.362
Published online Nov 16, 2010. doi: 10.4253/wjge.v2.i11.362
Table 1 Patient data for those with pancreatic lesions definitively diagnosed as benign or malignant (not all laboratory data were available for each patient)
| Malignant (n = 49) | Benign (n = 12) | |
| Age [median (range)] | 61 (34-88) | 60 (15-73) |
| Sex (M:F) | 27:22:00 | 8:04 |
| Location of pancreatic lesion | ||
| Head/uncinate process | 39 | 10 |
| Body | 9 | 2 |
| Tail | 1 | 0 |
| Serum enzymes [median (range)] | ||
| Total bilirubina (mg/dL) | 3 (1-28) | 1 (0-5) |
| AST (U/L) | 63 (11-603) | 35 (13-182) |
| ALT (U/L) | 74 (5-694) | 33 (13-167) |
| ALP (U/L) | 211 (54-1307) | 136 (59-1409) |
| Amylase (U/L) | 94 (15-182) | 80 (11-285) |
| Lipase (U/L) | 26 (13-199) | 29 (16-95) |
| Serum tumor markers [median (range)] | ||
| CEA (ng/mL) | 5 (1-403) | 3 (0-32) |
| CA19-9a (U/mL) | 339 (0-9929) | 28 (0-1507) |
Table 2 Distribution of positive tumor marker stains, alone or in select parallel combinations, according to cytology and final diagnosis
| Malignant (n=49) | Final diagnosis cytology | Benign (n=12) | ||||||
| Benign (n=8) | Atypical (n=17) | Suspicious (n=4) | Malignant (n=20) | Benign (n=5) | Atypical (n=7) | Suspicious (n=0) | Malignant (n=0) | |
| 1 | 4 | 0 | 9 | p53 | 0 | 0 | 0 | 0 |
| 2 | 4 | 0 | 14 | Ki-67 | 0 | 0 | 0 | 0 |
| 6 | 8 | 1 | 15 | CEA | 4 | 3 | 0 | 0 |
| 4 | 10 | 0 | 13 | CA19-9 | 1 | 2 | 0 | 0 |
| 2 | 6 | 0 | 16 | p53:Ki-67 | 0 | 0 | 0 | 0 |
| 6 | 12 | 1 | 17 | p53:Ki-67:CEA | 4 | 3 | 0 | 0 |
| 5 | 14 | 0 | 19 | p53:Ki-67:CA19-9 | 1 | 2 | 0 | 0 |
| 6 | 15 | 1 | 19 | All 4 stains | 4 | 3 | 0 | 0 |
Table 3 Diagnostic accuracy of routine cytology and immunohistochemistry, alone or in selected combinations, in detection of pancreatic cancer via endoscopic ultrasound-guided fine needle aspiration
| Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | PLR | NLR | |
| Cytology | 41 | 100 | 100 | 29 | ¥ | 0.59 |
| p53 + cytology | 51 | 100 | 100 | 33 | ¥ | 0.49 |
| Ki-67 + cytology | 53 | 100 | 100 | 34 | ¥ | 0.47 |
| CEA + cytology | 71 | 42 | 83 | 26 | 1 | 0.7 |
| CA19-9 + cytology | 69 | 75 | 92 | 38 | 3 | 0.41 |
| p53+Ki-67 + cytology | 57 | 100 | 100 | 36 | ¥ | 0.43 |
| p53+Ki-67 + CEA+cytology | 80 | 42 | 85 | 33 | 1 | 0.49 |
| p53+Ki-67 + CA19-9 + cytology | 80 | 75 | 93 | 47 | 3 | 0.27 |
| All 4 stains + cytology | 86 | 42 | 86 | 42 | 1 | 0.34 |
Table 4 Diagnostic accuracy of immunohistochemistry, alone or in selected combinations, as applied only to cytologically benign, atypical and suspicious specimens
| Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | PLR | NLR | |
| p53 | 17 | 100 | 100 | 33 | ¥ | 0.83 |
| Ki-67 | 21 | 100 | 100 | 34 | ¥ | 0.79 |
| CEA | 52 | 42 | 68 | 26 | 1 | 1.16 |
| CA19-9 | 48 | 75 | 82 | 38 | 2 | 0.69 |
| p53 + Ki-67 | 28 | 100 | 100 | 36 | ¥ | 0.72 |
| p53 + Ki-67 + CEA | 66 | 42 | 73 | 33 | 1 | 0.83 |
| p53 + Ki-67 + CA19-9 | 66 | 75 | 86 | 47 | 3 | 0.46 |
| All 4 stains | 76 | 42 | 76 | 42 | 1 | 0.58 |
- Citation: Jahng AW, Reicher S, Chung D, Varela D, Chhablani R, Dev A, Pham B, Nieto J, Venegas RJ, French SW, Stabile BE, Eysselein VE. Staining for p53 and Ki-67 increases the sensitivity of EUS-FNA to detect pancreatic malignancy. World J Gastrointest Endosc 2010; 2(11): 362-368
- URL: https://www.wjgnet.com/1948-5190/full/v2/i11/362.htm
- DOI: https://dx.doi.org/10.4253/wjge.v2.i11.362
